Download image:

Elizabeth B. Andrews

Vice President, Pharmacoepidemiology and Risk Management, RTI-HS

Elizabeth Andrews, PhD, is the vice president of Pharmacoepidemiology and Risk Management at RTI Health Solutions. Dr. Andrews provides consultation for pharmaceutical companies and the U.S. Food and Drug Administration on therapeutic risk management and pharmacoepidemiology, and she directs research programs that evaluate drug safety and compliance with prescribing and treatment guidelines. She oversees the conduct of large, prospective patient registries, web-based surveys, and studies using large existing databases. Dr. Andrews has worked extensively in the areas of HIV and sexually transmitted diseases, birth defects and neonatal health, asthma and chronic obstructive pulmonary disease, and irritable bowel syndrome. She is a fellow and past president of the International Society for Pharmacoepidemiology, and coeditor of Pharmacovigilance. She is an adjunct associate professor of the University of North Carolina School of Public Health and School of Pharmacy, and a member of the Steering Committee for the Innovation in Medical Evidence Development and Surveillance (IMEDS) Program of the Reagan Udall Foundation for the FDA.


PhD, Epidemiology, University of North Carolina at Chapel Hill; MPH, Health Policy and Administration, University of North Carolina at Chapel Hill.

Latest Publications

Andrews, E.B., Gilsenan, A.W., Midkiff, K.D., & Harris, D.H. (2015). Comments on Bang et al.: The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporosis International, Advance Online Publication .
Andrews, E.B., Margulis, A.V., Tennis, P., & West, S.L. (2014). Opportunities and challenges in using epidemiologic methods to monitor drug safety in the era of large automated health databases. Current Epidemiology Reports, 1 (4):194-205.
Namazy, J., Cabana, M.D., Scheuerle, A.E., Thorp, J.M., Chen, H., Carrigan, G., Wang, Y., Veith, J., & Andrews, E.B. (2014). The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy. Journal of Allergy and Clinical Immunology, Advance Online Publication .
Moride, Y., Andrews, E., Perez-Gutthann, S., Soriano-Gabarro, M., Heaton, S., Suzart-Woischnik, K., et al. (2014). Challenges in Risk Minimization Evaluation: CIOMS Working Group IX Consensus and Recent Field Experience, Pharmacoepidemiology and Drug Safety, 23 (Suppl. 1):41-42.
Mines, D., Tennis, P., Curkendall, S.M., Li, D.-.K., Peterson, C., Andrews, E.B., Calingaert, B., Chen, H., Deshpande, G., Esposito, D.B., Everage, N., Holick, C.N., Meyer, N.M., Nkhoma, E.T., Quinn, S., Rothman, K.J., et al. (2014). Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiology and Drug Safety, 23 (10):1017-1025.
View all publications by Elizabeth B. Andrews (132)


  • Drug Safety
  • Therapeutic Risk Management
  • Therapeutic Outcomes and Safety